Silexion Therapeutics Updates Clinical Timeline for Lead Candidate SIL 204

What Happened
On August 10, 2026, Silexion Therapeutics Corp. (SLXN) filed a Form 8-K (Regulation FD disclosure) to furnish an updated corporate presentation titled “Silencing Oncogenes at the Level of Gene Expression.” The presentation includes an updated timeline for the expected clinical testing and regulatory approval process for the company’s lead product candidate, SIL 204. A copy of the presentation was furnished as Exhibit 99.1 to the Form 8-K.

Key Details

• Filing date: August 10, 2026 (Form 8-K, Item 7.01 – Regulation FD Disclosure).
• Document: Corporate presentation titled “Silencing Oncogenes at the Level of Gene Expression” (Exhibit 99.1).
• Main update: Revised timeline for expected clinical testing and regulatory approval of lead candidate SIL 204.
• No earnings, financial results, or executive changes were reported in this filing.

Why It Matters
An updated clinical and regulatory timeline is a material operational milestone for a biotech company: it can change expectations for when clinical data, regulatory submissions, or other value-driving events may occur. Investors should review the furnished presentation for specific milestone dates and planning assumptions. This 8-K is a disclosure of information rather than a financial update—monitor future filings or press releases for related clinical progress, trial starts, or regulatory filings.